RxDoctor Payments Data

Bao Nguyen Phuc, MD

Family Medicine · Fort Worth, TXNPI 1518094317

Payments from drug & device makers

$6,001in general payments, 2019–2025

Across 306 payments — averaging $19.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biohaven Pharmaceuticals, Inc.$1K
  • Boehringer Ingelheim$1K
  • AbbVie$552
  • AstraZeneca$432
  • Lilly USA, LLC$414
  • Merck$351
  • plus $2K from 19 others

What the payments were for

  • Consulting fees$1,20020%
  • Food & beverage$4,72779%
  • Education$741%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,001 in reported general payments places this provider in the 85th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$10,688
Medicare patients
26
Services billed
167

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide77$78,202
FarxigaDapagliflozin Propanediol53$67,937
JardianceEmpagliflozin31$49,641
TrulicityDulaglutide35$34,798
Xigduo XrDapaglifloz Propaned/Metformin26$26,841
MounjaroTirzepatide16$20,592
Breztri AerosphereBudesonide/Glycopyr/Formoterol21$13,850
Synjardy XrEmpagliflozin/Metformin Hcl12$7,958
BelsomraSuvorexant13$5,751
Olmesartan Medoxomil81$1,923
Rosuvastatin Calcium193$1,309
Nebivolol Hcl16$1,250
Atorvastatin Calcium139$1,174
Irbesartan69$816
Amlodipine Besylate147$703

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere$432$81,78774 claims
Novo NordiskOzempic$323$78,20277 claims
Boehringer IngelheimJardiance, Synjardy Xr$1,181$57,59943 claims
Lilly USA, LLCTrulicity, Mounjaro$414$55,39051 claims
MerckBelsomra$351$5,75113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Fort Worth

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →